

Our Ref: 36/2022  
JANUARY 2022

## Re: Your request made under the Freedom of Information Act 2000

1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreous injections or implants) for each of the following eye conditions:

- Wet Age-Related Macular Degeneration (wAMD)
- Diabetic Macular Oedema (DMO)
- Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)
- Any other eye condition

Eye Condition	Number
Macular degeneration	1386
Diabetic macular oedema	492
Retinal vein occlusion	407
Other Eye Condition	5
<b>Grand Total</b>	<b>2290</b>

2. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2021:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021.

### Number of Injections/Implants: Sep to Dec 2021

Treatment	Eye Conditions		
	wAMD	DMO	RVO
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Fluocinolone acetonide			
Ranibizumab			

There is clinically no clinical coding or reconciliation that is able to distinguish between wet and dry macular degeneration. Therefore, the Trust is unable to respond to this question.

We cannot answer this question we do not record indication/diagnosis data on the pharmacy system